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ABSTRACT
Background: The Base of the Pyramid (BoP) project is a public–private partnership initiated
by Novo Nordisk that aims to facilitate access to diabetes care for people at the base of the
economic pyramid in low- and middle-income countries (LMICs). In Kenya, the BoP, through
a partnership model, aims to strengthen five pillars of diabetes care: increased awareness of
diabetes; early diagnosis of diabetes; access to quality care by trained professionals; stable
and affordable insulin supply; and improved self-management through patient education.
Objectives: This study evaluates the extent to which BoP Kenya is scalable and sustainable,
whether stakeholders share in its value, and whether BoP Kenya has improved access to
diabetes care.
Method: The Rapid Assessment Protocol for Insulin Access (RAPIA), an approach developed
to provide a broad situational analysis of diabetes care, was used to examine health infra-
structure and diabetes care pathways in Kenya. At the national level, the RAPIA was applied in
a SWOT analysis of the BoP through in-depth interviews with key stakeholders. At individual
and county health system levels, RAPIA was adapted to explore the impact of the BoP on
access to diabetes care through a comparison of an intervention and control county.
Results: The BoP was implemented in 28 of 47 counties in Kenya. Meru, a county where BoP
was implemented, had 35 of 62 facilities (56%) participating in the BoP. Of the five pillars of
the BoP, most notable progress was made in achieving the fourth (stable and affordable
insulin supply). A price ceiling of 500KSh (US$5) per vial of insulin was established in the
intervention county, with greater fluctuation and stock-outs in the non-intervention county.
Despite reduced insulin costs, many patients with diabetes could not afford the additive
expenses of monitoring, medicines, and travel. Less progress was made over the other pillars,
which also faced challenges to sustainability and scalability.
Conclusion: In the context of the rising prevalence of non-communicable diseases in LMICs,
cross-sector approaches to improving access to care are increasingly needed. Public–private
partnerships such as the BoP are necessary but not sufficient to ensure access to health care
for people with diabetes at the base of the economic pyramid in Kenya.
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Background
Between 347 and 422 million adults are affected by
diabetes around the world [1,2]. The prevalence of
diabetes is predicted to rise to 642 million by 2040
and disproportionally affect low- and middle-income
countries (LMICs), where 80% of patients are located
and where 75% of the burden of mortality from non-
communicable diseases (NCDs) occurs [2,3].
In Kenyan adults, the nationally adjusted preva-
lence of diabetes was estimated to be 3.6% in 2013
and is projected to rise to 4.4% in 2035 [4]. More
than 8,700 diabetes-related deaths were registered in
Kenya in 2015, almost all under 60 years of age [5].
Diabetes prevalence is higher in urban populations
and in men [5], however, most national estimates are
derived from adult populations and the prevalence of
Type 1 diabetes in children and adolescents is largely
unknown [6]. While diabetes is considered under-
quantified in this context [7], it is estimated that as
many as 60% of people with diabetes in Kenya
remain undiagnosed [3]. The number of adults with
Type 2 diabetes prescribed insulin in Kenya is also
not known, although a household survey performed
in Kibera, an informal settlement in Nairobi, esti-
mated that, for those with a formal diagnosis of
diabetes, 22.6% used insulin [8]. The rise of NCDs
such as diabetes places a double-burden on an already
strained health-care system and presents a challenge
for the health-care system to respond to the differing
needs of both acute and chronic diseases.
Life expectancy and quality of life for people with
diabetes can improve, and disease control is possible
when diabetes is detected early and managed appro-
priately [9]. However, if undetected or poorly
CONTACT Geordan D. Shannon geordan.shannon.13@ucl.ac.uk Institute for Global Health, University College London, 3rd floor, Institute of
Child Health, 30 Guilford Street, London WC1N 1EH, UK
GLOBAL HEALTH ACTION
2019, VOL. 12, 1605704
https://doi.org/10.1080/16549716.2019.1605704
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
managed, diabetes can lead to severe and permanent
complications including loss of vision, cardiovascular
disease, end-stage renal disease, and amputation of
the lower extremities [10]. To address this, a basic
package of diabetic care should include a healthy diet
and physical exercise, blood glucose monitoring,
blood pressure control, foot and eye care, and
a regular supply of insulin or anti-hyperglycaemic
medication if indicated [10]. In LMICs like Kenya,
many patients struggle to receive this basic diabetes
care. They face several barriers to care that may
include distance to the health care facility, lack of
awareness, affordability of medicine, availability of
diagnostic and monitoring tests, and poor local
health system capacity [11,12].
To respond to this challenge, the Base of the Pyramid
(BoP) project, which is a public–private partnership,
aims to facilitate access to diabetes care for the working
poor in LMICs [13]. Initiated by Novo Nordisk in 2011,
BoP uses a range of different business models adapted
to improve health care for people with diabetes at the
base of the economic pyramid [14]. In Kenya, the BoP
programme’s objective is to bring together stakeholders
to ensure: increased awareness of diabetes; early diag-
nosis of diabetes; access to quality care by trained
health-care professionals; stable and affordable insulin
supply; and improved self-management through
patient education [14]. These are represented symboli-
cally by five pillars which constitute the BoP pro-
gramme (Figure 1) [15]. The BoP programme works
towards Goal 3 of the United Nations Sustainable
Development Goals (SDGs), namely ‘to ensure healthy
lives and promote well-being for all at all ages’ [16].
With this approach to improving diabetes care in
Kenya through a focus on national partnerships and
supply-chain strengthening, it was important to
assess the impact of the programme holistically. We
undertook an independent evaluation of the BoP
programme in Kenya to gain insight into its effec-
tiveness, scalability, sustainability, and shared value.
The specific objectives of the evaluation were to
assess the extent to which BoP Kenya is scalable and
sustainable, understand whether all partners share
value in the Kenyan BoP scheme, and investigate
whether it has improved access to diabetes care.
Methods
Setting
With decentralisation of power following the 2010
Kenyan Constitution, Kenya’s 47 Counties each man-
age their own health systems, including services for
NCDs. County health services are arranged into six
levels of increasing comprehensiveness. Level 1 are
community units that provide community-based
care. Level 2 are dispensaries that provide immunisa-
tions, basic antenatal care and other primary health
care. Level 3 facilities are health centres that are larger
than level 1 and 2 facilities and have more compre-
hensive services, which may involve the dispensation
of certain medications and some degree of basic
inpatient management. Level 4 are sub-county hospi-
tals, and Level 5 services represent the county referral
hospital. Finally, Level 6 services are the national
referral hospitals that are located in Nairobi.
Although the Kenyan Constitution declares health
to be a universal right [17], progress towards universal
health coverage (UHC) in Kenya has been limited
[18,19]. A quarter of Kenyan households are further
than 8 km away from any sort of health care facility,
23% of Kenyans fail to utilise health care services when
they are in need of it and only 25% have some form of
health insurance [20]. There was an average life expec-
tancy of 61 (male) and 66 (female) years in 2015 [10].
Out of pocket (OOP) spending as a proportion of total
Figure 1. The five pillars of the BoP programme.
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health expenditure decreased from 50% in 2010 to
26% in 2014 but still remains high [21].
NCDs, including diabetes, are increasingly recog-
nised health challenges. The 2015–2020 Kenya
National Strategy for the Prevention and Control of
NCDs identifies diabetes as one of the four largest
chronic disease burdens and has established
a roadmap for health promotion, risk factor reduc-
tion, and health systems strengthening [22].
Additionally, the National Hospital Insurance Fund
(NHIF) recently launched a specific chronic disease
package of care [23]. Despite these national initia-
tives, systems of diabetes care remain inconsistent at
the sub-county and county levels, and data on dia-
betes are severely limited.
The Kenyan base of the pyramid (BoP)
programme
The BoP was designed to address health care for people
with diabetes at the ‘base of the economic pyramid’ in
Kenya and has been implemented in 28 of 47 counties in
Kenya [14.15]. Although NovoNordisk is a leading insu-
lin producer, the BoP targets wider aspects of diabetes
care (Figure 1). Specific programme activities include
establishing centres of excellence for diabetes care at
local public hospitals, free screening and awareness cam-
paigns, the development of patient educationmaterials in
local languages, as well as training of health care profes-
sionals, pharmacists and nutritionists in diabetes preven-
tion and care [14]. BoP partners in Kenya include the
Kenyan Ministry of Health, County Government
Departments of Health, national and local drug distribu-
tion networks (Phillips Pharmaceuticals Ltd, Mission for
Essential Drugs and Supplies, MEDS), Faith-based orga-
nisations (FBOs) including the Kenya Conference of
Catholic Bishops (KCCB) and Christian Health
Association Kenya (CHAK), and the Kenya Defeat
Diabetes Association (KDDA), a national patient advo-
cacy and support network [14]. The BoP specifically
works with FBOs who provide primary care at Level 2
and 3 facilities (see Settings section, above, for an expla-
nation of levels of care). To limit price mark-ups in
the insulin supply chain, while retaining incentives
for regular insulin supply, Novo Nordisk signed
a memorandum of understanding with every link in the
insulin distribution chain, making it difficult for distri-
butors and actors in the value chain to exceed the
agreed price of 500 Kenyan Shillings (KSh), or about US
$5, per vial.
Rapid assessment protocol for insulin access
(RAPIA)
We adapted the Rapid Assessment Protocol for
Insulin Access (RAPIA) in order to evaluate the
BoP in Kenya [24]. The RAPIA approach was
developed to provide a broad situational analysis of
diabetes care, to generate recommendations for
health service strengthening to national Ministries
of Health and Diabetes Associations. The RAPIA
uses a range of approaches to collect information,
including interviews, questionnaires, focus group dis-
cussions, site visits, and document reviews from var-
ious stakeholders [15,24]. This strategy is used to
understand the path of insulin and availability of
infrastructure, personnel, and resources to diagnose,
treat, and care for patients with diabetes and tries to
identify barriers that may exist at different levels of
the health-care system. RAPIA has the advantage of
being both rapid and low-cost, while still yielding
data of a high scientific standard. RAPIA has been
previously used in Zambia, Mozambique and
Mali [25].
The RAPIA collects structured information from the
Macro, Meso, and Micro levels of the health system.
Macro-level information represents the national level
structure of health care services, such as government
ministries, national organisations, and other centralised
services. Meso-level information is derived from inter-
views with county health authorities or pharmacies.
Micro-level information is collected from individual
patients, carers, and service providers [24].
We adapted the RAPIA to the Kenyan health system
and tailored it to suit the evaluation of the Base of the
Pyramid Project (Appendix 1). At national (Macro)
level, the RAPIA was applied in a SWOT analysis of
the scalability, sustainability, and shared value in the
BoP through 15 stakeholder interviews, national-level
process mapping and structured observations in select
fields sites. At individual (Micro) and county (Meso)
health system levels, RAPIA was adapted to explore the
impact of the BoP on access to diabetes care through
a comparison of an intervention and control county.
We used a combination of in-depth interviews, clinic
observations, document reviews and focus group dis-
cussions to gather information.
Comparison of intervention and control counties
For this study, the RAPIA approach was adapted to
facilitate comparison between two counties, one with
and one without the BoP in Kenya.
The intervention county was selected in a purposive
manner from the Kenyan counties in receipt of the
programme, by considering firstly if all the components
of the BoP programme and integrated diabetes care had
been implemented (including patient education, insulin
supply chain strengthening, formation of diabetic sup-
port groups (DSGs), and staff support systems), and
secondly that it was a ‘representative’ Kenyan county.
To ensure the representativeness of the county, we
analysed geographic, demographic, health and eco-
nomic indicators of all counties included in the BoP.
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We selected Meru county as our intervention county
based on this analysis and reassurance from the BoP
management team that all components of the pro-
gramme were implemented. This county was then pur-
posively matched to a comparison or control county
based on the same geographic, demographic, health and
economic indicators, in which the BoP was not imple-
mented. Based on this process, Trans Nzoia was
selected as the control county. The study sites are
detailed in Table 1.
Data collection
At the national (Macro) level, we performed a total of
fifteen in-depth interviews with key stakeholders
(Table 2). In addition, we undertook structured
observations at the Nakuru Centre of Excellence
Launch, the World Diabetes Day conference in
Nairobi, and with each of the seven national BoP
partners. Macro-level interviews established accept-
ability, scalability, and sustainability of the BoP in
Kenya.
In Meru, the intervention county, a total of 22 in-
depth interviews and five focus group discussions
(FGDs) were conducted (Table 2). In the control
county, Trans Nzoia, a total of 24 in-depth interviews
and three FGDs were conducted. Data were collected
from patients with diabetes, medical staff, community
health workers, pharmacists, lab technicians and health
service administrators. The Meso- and Micro-level
interviews explored sustainability and value sharing,
while also describing barriers to care and the effect of
the BoP on patient care. In addition, at Meso andMicro
levels, data on the five core modalities of BoP including
increased diabetes awareness, early diagnosis, access to
care, stable and affordable insulin supply and improved
patient management, were collected.
Where possible and appropriate, data from qualita-
tive key informant interviews were supplemented with
available secondary data provided by Novo Nordisk.
Secondary data from Novo Nordisk included informa-
tion on the number of clinics in operation, as well as the
nature and quantity of products and services supplied.
The research team established a clear division between
Novo Nordisk and the research process to reduce bias
and minimise contaminations.
Research access and ethics
Data collection occurred between October and
December 2016. UCL partnered with the Stockholm
Environment Institute Africa (SEI-Africa), a not-for-
profit research agency based inNairobi, for local expertise
and research support. The Kenyan Novo Nordisk Office
facilitated field research and interviews with all Macro-
level stakeholders. Novo Nordisk also assisted in setting-
up Meso- and Micro-level interviews in Meru county.
Researchers from SEI-Africa and central FBO facility
coordinators helped in making introductions locally in
Trans Nzoia. All participants were recruited through
local health services and consented to their involvement
Table 1. County summary of Meru and Trans Nzoia.
Indicator Meru Trans Nzoia
Location 300 km northeast of
Nairobi
390 km northwest of
Nairobi
Population 1,584,575 956,559
% of
population
located in
urban areas
16% 20%
Gross
domestic
product
(GDP) per
capita
US$533 US$349
GINI index 0.348 0.360
Educational
status
18% secondary or above
62% primary education
only
21% no formal
education
21% secondary or above
59% primary
education only
20% no formal
education
Health system
overview
116 public facilities, 66
FBOs, 3 non-
government
organisations, and 20
private sector owned
facilities. 58% of all
services are run through
the government
54 public facilities, 15
FBOs, 5 non-
government
organisations and 78
private sector owned
facilities, generally
small private clinics
Data sources [26–29].
Table 2. Summary of Macro-, Meso-, and Micro-level interviews.
2A: MACRO-level 2B: MESO-andMICRO-level 
KDDA: Kenyan Defeat Diabetes Association; CHAK: Christian Health Association Kenya; FBO: Faith-based organisation; KCCB: Kenyan Conference of
Catholic Bishops; MEDS: Mission for Essential Drugs and Supplies; MoH: Ministry of Health; CoE: Centre of Excellence.
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in the interview or focus group discussion process,
including the use of audio-visual recordings.
Researchers maintained independence from Novo
Nordisk throughout the evaluation, and fieldwork and
findings were not shared with Novo Nordisk until the
conclusion of the study.
Ethical approval for the research was granted by
the UCL Research Ethics Committee (5406/002) and
the Maseno University Ethics Committee (00334/16).
Interviews and analysis
A teamof three people (supervisor, interviewer/translator
and note-taker) conducted all field interviews. We per-
formed the interviews in either Kiswahili or English.
Interviews with stakeholders, staff and officials were per-
formed in English, while interviews with patients, carers
and merchants were performed in Kiswahili. After
obtaining consent, all interviews were tape-recorded
and detailed interview notes taken. Data collection and
analysis took place simultaneously, and an initial analysis
of each interview was made before the next interview.
This allowed modification of the interview guides for the
next interview if important issues emerged. Interview
notes were thematically analysed, and a sample of the
tape recordings was transcribed and translated by
amember of the team in order to triangulate and validate
the findings from the interview notes.
Results
Our key findings are presented in terms of the five
pillars of the BoP: increased awareness of diabetes;
early diagnosis of diabetes; access to quality care by
trained health-care professionals; stable and afford-
able insulin supply; and improved self-management
through patient education.
Awareness of diabetes
At a national level, Novo Nordisk activities aimed
to encourage awareness of diabetes and engagement
in diabetes care. Their reported focus was on stake-
holder engagement, networking across sectors, and
specific educational activities. BoP partners also
attempted to raise awareness of diabetes through
annual education days or education campaigns.
However, at Meru County level, there were limited
BoP outreach activities which resulted in low aware-
ness of diabetes and minimal understanding of the
BoP and Novo Nordisk. There was local enthusiasm
for such outreach activities and this represents
a future opportunity. Although BoP-related out-
reach and education activities were not present in
Trans Nzoia, there was an annual march organised
around World Diabetes Day to encourage greater
awareness and education about diabetes and to
encourage screening. This was coordinated by the
Kitale DSG alongside the main government referral
hospital in Kitale. We also observed non-BoP com-
munity health volunteer models of outreach operat-
ing in both Trans Nzoia and Meru; this approach
was identified by interview participants as favour-
able for the local context.
Early diagnosis
In Meru, the BoP facilitated some free screening
activities at Level 4 FBO facilities between 2013 and
2015, involving free finger stick blood glucose testing
with a glucose meter along with education and free
tea. This campaign was perceived by staff as being
successful in attracting patients to health care facil-
ities and improving initial contact with the health-
care system. However, these campaigns were report-
edly short-lived. Funding for these activities has since
ceased, and some FBO facilities felt a sense of dis-
appointment and frustration that the costs of screen-
ing were now passed to the patient and that,
subsequently, less people accessed screening and
early diagnosis. Furthermore, access to regular blood
glucose level (BGL) testing with a finger stick glucose
meter – as the most routinely used tests to guide both
diagnosis and management of diabetes – were per-
ceived to be unaffordable on a regular basis. Thus,
many patients were being managed without a good
sense of their BSL profile. One practitioner described
it as ‘like driving a car in the dark without the
lights on.’
There were no coordinated community screening
or early diagnosis activities in place in Trans Nzoia.
This meant that people risked presenting in later
stages of their disease and with advanced complica-
tions, placing higher burden on the health-care sys-
tem through increased intensity of care and
resources. In both locations, diabetes groups also
felt that regular BSL testing was unrealistic and too
expensive to access on a routine basis as required for
adequate diabetes management.
Access to quality care by trained health-care
professionals
Barriers to access were evaluated from patient per-
spectives in both counties. Poverty, geography, edu-
cation, gender, and health system limitations were
barriers to accessing appropriate diabetes care. The
combined costs of seeking health care were often
insurmountable and were identified as one of the
most prominent issues in obtaining adequate health
care. Costs involved transport to clinics, supplemen-
tary equipment costs (such as syringes and glucose
meters), providing healthy food, opportunity costs of
missing a day of work, upfront consultation and
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diagnostic fees, and medication costs. Patients
reported they were unable to afford essential medi-
cines because of poverty, and trade-offs in household
financial decisions between food, education, trans-
port, and medicine were common. One commonly
reported behaviour was that patients would either not
use insulin when medically indicated or would part-
treat themselves with insulin in order to make it last
longer. Improved affordability of insulin was there-
fore not sufficient to overcome additive costs of
accessing care.
Through the BoP programme, some health care
professionals in Meru received training in the form
of printed resources and annual educational activities.
The printed materials were greatly valued by both
patients and staff and were in high demand.
Training was offered annually to only one or two
staff per facility, meaning that the programme did
not cover the demand for education. In addition,
the training events took place in centrally located
venues, meaning that participants had to travel long
distances. In the control county, staff did not have
access to formal educational opportunities, however,
one motivated staff member at a Trans Nzoia FBO
lobbied Novo Nordisk to provide access to a range of
printed educational resources which they informally
distributed to their network. An additional challenge
to health worker capacity-building in both locations
was the reportedly high staff turnover rates, where
recipients of BoP training left for other facilities. This
translated into low awareness of the BoP programme
and lower levels of diabetes knowledge in rural facil-
ities. The mentoring component of the BoP education
package was seen as valuable by those involved but
needed expansion to ensure all rural staff are linked
to greater support and expertise.
Stable and affordable insulin supply
In Meru county, a more consistent supply of insulin
was identified: one unit of Mixtard® (a suspension
containing both fast-acting – soluble – and inter-
mediate-acting – isophane – insulin) was being sold
at a price of 500 KSh (about US$5). This stability in
supply has effectively established a price ceiling of
500–600 KSh for Mixtard® insulin both within parti-
cipating facilities and in surrounding markets and
private pharmacies in Meru, where vials were pre-
viously sold for up to 1,800 KSh (about US$18)
(Table 3). In Trans Nzoia, where the BoP was not
formally running, there was comparatively greater
fluctuation in the price of a vial of insulin. Insulin
was occasionally available more affordably at govern-
ment clinics in both locations, where the subsidised
price was 200 KSh (about US$2). However, insulin at
this price and in these clinics was found to be
frequently out of stock, meaning that patients had
to purchase it privately and at much higher prices
than the price ceiling in BoP areas.
Given the high rates of government stock-outs of
insulin and other medicines, consistency in supply
was highly valued by the interviewed patients.
Despite more consistently reduced insulin costs
in the BoP areas, many patients with diabetes could
not afford the combined direct expenses of regular
monitoring, testing, medical consultations and
medicine. Direct non-medical expenses like the
costs of travelling and also lost wages (or opportu-
nity cost) of care seeking, further increased the
financial burden of diabetes care (Table 3).
Average GDP per capita in Meru was US$533 (US
$1.51/day), and Trans Nzoia was US$349 (US$0.99/
day), meaning that the average person in these
counties lives below the poverty line of US$1.90 -
per day. For many who were living at or below the
poverty line, the costs relating to seeking medical
care were often insurmountable. Patients inter-
viewed experienced competing financial priorities
forcing a difficult choice between food, living
expenses, education, and essential health care.
Self-management through patient education
To address some barriers to diabetes care, multiple
DSGs were established in Meru by both FBOs (BoP)
and the government (non-BoP), which took normally
place on the diabetes clinic days. These groups
encouraged patients to share experiences and strate-
gies to cope with diabetes. However, DSGs ran on
limited resources and relied on individual members
taking time to attend the group. Groups felt under-
supported and under-
resourced and thus were unable to provide the opti-
mal level of support for their members. In addition,
the price of consumables for diabetes care, from
glucose meter strips to syringes, were seen as additive
expenses that were out of reach for many. DSGs
suggested models of support via joint purchasing of
glucose meter units and strips to share around the
patient group.
Discussion
The objectives of this study were to explore whether
the Kenyan BoP scheme is sustainable, understand
whether all partners share value in the BoP, assess the
extent to which BoP is scalable, and investigate
whether BoP has improved access to diabetes care.
We explored these areas over the five pillars of the
BoP, above.
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Sustainability, scalability, shared value, and
access to diabetes care
One of the main focal points of sustainability of the
BoP model was the price point of insulin, which was
seen as a balance between charity and profit, and as
a way to ensure the financial durability of the BoP.
The lower price of insulin from national suppliers led
to an increase in orders placed at national level;
however, it has not yet translated into a financially
sustainable model for Novo Nordisk. Despite this,
a secure system of insulin ordering, procurement,
and supply now exists as a result of BoP.
At the national level, all partners had a strong
sense of shared value in BoP. Despite reports that
national BoP partner organisations felt stretched
financially to provide services (insulin, staff education
or staff support), they felt that the service they pro-
vided was an important one. However, local health
care providers felt left behind and require further
support to ensure they, too, feel a sense of ownership
and shared value in the programme.
In terms of scale, the BoP may, in fact, benefit from
more focused activities at the county-level to enhance
overall effectiveness. Despite strong Macro-level activ-
ities, many of our findings suggest that front-line staff
and patients do not benefit from the full potential of
the BoP. Therefore, prior to expansion of the pro-
gramme, greater focus on strengthening existing com-
ponents is necessary. The impact of the BoP on
national insulin supply chains may offer some benefit
to neighbouring countries through partners such as
MEDS who supply to East Africa. At the micro level,
because of the nature of human movement and small-
scale business in Kenya, the lower price of insulin in
BoP counties such as Meru may also have a natural
flow-over effect into non-intervention counties.
Of all the factors influencing access to care, we
found that the consistency and availability of insulin,
along with a price ceiling of around US$5 for a vial of
insulin, were valued in the context of high stock-outs
and price fluctuations in government health services.
However, access to affordable insulin was only one
piece of a larger and more complex puzzle. The
additive costs of seeking medical treatment meant
that many still could not afford adequate diabetes
care. In the context of high rates of poverty in rural
Kenya, many individuals and households faced diffi-
cult choices about spending the limited resources
they had. For many, this meant that their diabetic
care was severely compromised.
Out-of-pocket health expenditure (expressed as %
of current health expenditure) in Kenya in 2015 was
33% [30] This means that in a large number of cases,
individuals pay for health care from limited personal
savings. This scenario places households at risk of
catastrophic health spending and subsequent
impoverishment. The average Kenyan household
spends over a tenth of their annual budget on health
care payments, however, this is higher for the poorest
of Kenyan households who spend a third of their
resources on health care payments [30]. About 1.3%
of Kenyans are pushed below the international pov-
erty line annually because of health care payments
[19,30]. The BoP has the opportunity to alleviate
some of this burden through the provision of quality
and affordable care, through strengthening the pillars
of the BoP beyond insulin provision (awareness, diag-
nosis, quality of care). In the context of Universal
Health Coverage and the SDGs goal of equality of
access to health care, it is important to improve
components and systems of health care for NCDs
such as diabetes.
Strengths, weaknesses, opportunities, and threats
The main strengths of the BoP included networking
and stakeholder engagement through Macro-level
educational activities and partnerships. The BoP pro-
gramme was the first of its kind in Kenya and has
initiated a network of action around diabetes care
and has contributed to opening up the conversation
around NCDs at a national level. Another strength of
the BoP is the ability to price-regulate vials of insulin
to 500KSh at the consumer level. This has ensured
a more consistent demand and supply cycle.
However, in comparison with other ongoing front-
line programmes, the BoP initiative is relatively
unknown among patients and lower level health
workers. Although it is not a priority of the pro-
gramme, some element of ‘branding’ at the patient
and service provider level could ensure the messages
and impact of the programme are better known and
more effectively taken-up at the micro- and meso-
level. Despite a very strong macro-level approach to
insulin provision and public–private partnerships, the
micro- and meso-level activities relating to the five
pillars of the BoP need to be strengthened to max-
imise overall programme effectiveness. With the view
of transitioning towards UHC, there are many issues
around infrastructure and sustainability to address in
conjunction with county governments and the
Ministry of Health.
As with many LMICs, data availability, and data
systems are significant limiting factors in research on
NCDs in Kenya. At present, we have very limited
information on the prevalence of diabetes at county
or sub-county levels. Data limitations in Meru and
Trans-Nzoia counties made a quantitative evaluation
of the impact of the BoP programme impossible. The
BoP, as a coordinated and integrated programme
with a wide reach into rural and under-resourced
areas in Kenya, has the opportunity to assist with
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the development and strengthening of data collecting
systems. This would not only be beneficial to the
evaluation of the BoP project itself but also would
benefit diabetes and NCD research in Kenya and
beyond. This project has the opportunity to encou-
rage the strengthening of local and national-level
health management information systems.
There is an opportunity to collaborate with inter-
ested partners in the delivery of a more holistic NCD
package. As identified above, a community health
volunteer model of outreach has the capacity to
increase community awareness and diagnosis and
would be an excellent model for collaboration. Novo
Nordisk has purposively taken the approach of part-
nering with a range of existing organisations to work
within existing national structures. The BoP has
focused on existing networks of FBOs around the
country, who have substantial rural coverage. A lot
of the network building has been at a national level,
which has meant there has been limited contact with
BoP activities ‘on the ground.’ There is the potential
to work closer with FBO partners and/or DSGs to
ensure greater support and capacitation of staff and
patients on the ground to enhance diabetic care.
A macro-level threat underlying the BoP activities
was the existence of multiple competing health care
priorities in Kenya, in addition to the historical legacy
of vertical programmes targeting singular communic-
able diseases. The Kenyan Ministry of Health’s
Department of Non-Communicable Diseases is driv-
ing increased focus on a number of NCDs and their
inter-relations, as well as coordinating multiple non-
governmental and governmental programmes.
A recent increase in national attention towards
NCDs has culminated in the publication of the
Kenya National Strategy for the Prevention and
Control of Non-Communicable Diseases, 2015–2020
[32]. The BoP has taken advantage of the willingness
expressed in the national NCD strategy of embracing
partnerships and utilising private sector capacity. But
there are many more opportunities for the BoP to
continue to expand the scope and reach of its work.
Research limitations and next steps
Our research was limited in the following ways. First,
the evaluation above occurred at the 5-year mark of the
BoP in Kenya. Embedding evaluation approaches into
the project planning cycle can lead to a greater under-
standing of the process of change as well as the overall
impact of the intervention. Second, the limited quanti-
tative data availability meant that we relied heavily on
fact-finding and qualitative interviews. Third, the bud-
get and timescales enabled only the RAPIA approach,
which is suitable for a rapid situational analysis and
systematic overview, rather than an in-depth evalua-
tion. The strength of the RAPIA, aside from its fast
timescale, was its agility to be adapted to the Kenya
context, as well as to position the impact of the BoP
within the levels ofKenya’s health system. Fourth,
because of the scope of the evaluation, we were only
able to select two counties (an evaluation and control
county) to compare, meaning we only captured
a snapshot of the complexities of diabetes care in
Kenya. Finally, while every effort was made to reduce
the influence of Novo-Nordisk on the findings, we
cannot entirely rule out the risk of positive bias.
At the Macro level, possible next steps for the BoP
would be to continue to align with the Ministry of
Health work plan and to expand a sense of national
ownership, not simply to operate as a stand-alone
project. Further, BoP Kenya may consider more stra-
tegic partnerships along to the pathway of diabetic
care, including suppliers of point of care diagnostics.
At the Meso Level, investment in health system infra-
structure such as diagnostic equipment and human
resources is critical; in particular, a focus on health
worker education and staff satisfaction could ensure
greater staff retention and continuity of care. At the
Micro level, increased community awareness is pos-
sible, but requires sustained efforts on behalf of the
BoP partners. This may include the enhanced role of
the peer mentor and diabetic support group activities.
Beyond awareness and education, there is an oppor-
tunity to enhance diagnosis through ensuring diag-
nostic equipment is reliably available closer to the
community.
Conclusion
In the context of rising prevalence of NCDs in
LMICs, improving access to diabetes care is essential.
BoP demonstrates that collaborative approaches to
improving access to diabetes care have the potential
for improving diabetes care, but require sustained
efforts at all levels of the health system and consid-
eration of barriers to care from patients’ perspectives.
Of the five pillars of the BoP, most notable progress
was made in achieving the fourth pillar (stable and
affordable insulin supply). Less progress was made
over the other pillars, which also faced challenges to
sustainability and scalability.
At the macro level, the BoP engaged stakeholders
at a national level to ensure structural change, but
needs to invest more in local approaches to overcom-
ing barriers to care, which may include supporting
local DSGs, enhancing self-monitoring with gluc-
ometers, community outreach, and greater capacity-
building in lower-level health centres. Our evaluation
also highlights priority areas for further improvement
including further reducing the overall financial bur-
den of diabetes care, scaling up the BoP to other
counties in Kenya and improving the visibility of
the education, awareness and screening programmes.
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Appendix 1.
Table A1. Adapting the RAPIA method to the Kenyan BoP Evaluation.
Stakeholder RAPIA interview themes Objectives addressed
MACRO-LEVEL INTERVIEWS
Novo-Nordisk ● Distribution of insulin
● Insulin tendering and purchase
● Value share to Novo-Nordisk
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP scalable?
● Is BoP sustainable?
● Is there shared value in
the scheme?
Phillips Pharmaceuticals Ltd ● Distribution of insulin
● Insulin tendering and purchase
● Value share to Phillips
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP scalable?
● Is BoP sustainable?
● Is there shared value in
the scheme?
Ministry of Health ● Organisation of diabetes care
● Resources for diabetes care
● National diabetes programmes
● Pricing of insulin
● Distribution of insulin
● Funding for insulin and diabetes
● Insulin tendering and purchase
● Educating patients
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP scalable?
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
Ministry of Trade ● Trade issues (laws, barriers)
● Trade infrastructure
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP scalable?
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
Ministry of Finance ● Funding of health system
● Taxes on insulin
● Funding for insulin and diabetes
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP scalable?
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
Local drug distribution networks (e.g. MEDS) ● Pricing of insulin
● Distribution of insulin
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Perceived value share from BoP
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
Faith-based associations, e.g. The Christian Health Association of
Kenya (CHAK) and the Kenya Conference of Catholic Bishops (KCCB)
● Organisation of diabetes care
● Resources for diabetes and insulin
● Distribution of insulin
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Perceived value share from BoP
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
(Continued )
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Table A1. (Continued).
Stakeholder RAPIA interview themes Objectives addressed
Diabetes Associations including Kenya Defeat Diabetes Association and
Diabetes Kenya Association
● Issues with diabetes and insulin
● Education campaigns
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Perceived value share from BoP
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
Central Medical Store/Kenya Medical Supplies Authority (KEMSA) ● Insulin tendering and purchase
● Insulin distribution and storage
● Insulin pricing
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for sustained
and up-scaled BoP activities
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
MESO-LEVEL INTERVIEWS
County/district health organisation ● Issues with diabetes and insulin
● Organisation of diabetes care
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for up-scaled
BoP
● Is BoP scalable?
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
Hospitals, clinics, health centres, dispensaries, etc. ● Treatment and management of
diabetes
● Access to appropriate tools to
diagnose and treat patients
● Infrastructure present and/or lack-
ing for insulin provision
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for up-scaled
BoP
● Is BoP sustainable?
● Is there shared value in
the scheme?
● Has BoP improved
access to diabetes care?
Laboratories ● Infrastructure for diagnosis and fol-
low-up
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Institutional support for up-scaled
BoP
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
Pharmacies ● Insulin distribution and storage
● Insulin pricing
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for up-scaled
BoP
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
MICRO-LEVEL INTERVIEWS
Health workers and traditional healers ● Problems encountered in diagnosis
and treatment of patients
● Training
● Infrastructure present and/or
lacking
● Tools present and/or lacking
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for up-scaled
BoP
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
(Continued )
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Table A1. (Continued).
Stakeholder RAPIA interview themes Objectives addressed
Market traders selling drugs ● Awareness of diabetes and Insulin
● Access to insulin for resale
● Pricing of insulin
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Stakeholder engagement in BoP
● Institutional support for up-scaled
BoP
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
Patients and carers ● Diagnosis
● Access to treatment
● Cost of treatment
● Awareness of diabetes
● Awareness of BoP
● Perceptions of BoP acceptability,
effectiveness and sustainability
● Is BoP sustainable?
● Has BoP improved
access to diabetes care?
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